INSIGHTS ON DRUG DEVELOPMENT
-
![pharma-development-GettyImages-2166352610]( "Streamlining Early Drug Development: Efficient Synthesis Of Highly Potent Compounds")
Streamlining Early Drug Development: Efficient Synthesis Of Highly Potent CompoundsDiscover how risk‑based, phase‑appropriate synthesis enables safe, efficient production of highly potent compounds while balancing speed, worker safety, and regulatory readiness in early development.
-
![icellis family]( "Streamline Your Workflow With An Innovative Fixed-Bed System")
Streamline Your Workflow With An Innovative Fixed-Bed SystemDiscover how an innovative fixed-bed system streamlines workflows and supports consistent, high-yield manufacturing across a range of applications.
-
![Multi ethnic lab team-GettyImages-1255978257]( "Evaluating Carryover When Using A TOC Analyzer")
Evaluating Carryover When Using A TOC AnalyzerAccurate TOC results shouldn’t depend on sample order. See how low-level measurements remain reliable even after high-TOC analysis, helping reduce false positives and streamline decisions.
-
![GettyImages-1751659695-laboratory-scientists-computer-analysis-evaluation]( "Doubling Up For Speed In Biomanufacturing")
Doubling Up For Speed In BiomanufacturingAccelerate drug development and reduce risk with parallel operations. Learn how leveraging CDMO partnerships while building internal capabilities can cut costs and speed your path to market.
-
Oral Delivery Of PROTACs: Integrating Molecular Design And Enabling Formulation8/20/2026
Explore how integrated molecular design and formulation strategies can overcome the unique oral-delivery challenges of PROTACs, transforming complex degraders into viable, scalable medicines.
-
New Approaches To Tailored Release Profiles7/7/2025
Tailored drug release is evolving from formulation tactic to precision therapy strategy, optimizing timing, site, and rate of delivery for improved patient outcomes.
-
Your AKTA Oligosynt™ System : It's More Than A Machine2/9/2026
Discover how early choices in oligo synthesis workflows shape performance. Learn what to consider across design, reagents, and system optimization to build a process ready for smooth scale‑up.
-
The Need For Speed: Early-Stage Dosage Form Development9/23/2026
The right formulation strategy can accelerate clinical timelines and set the stage for successful later-phase development.
-
Viral Gene Therapy: Reducing Costs To Improve Patient Access7/23/2025
Gene therapy is revolutionizing medicine with its potential to cure genetic disorders. As approvals rise, so do concerns about accessibility, with million-dollar price tags limiting patient access.
DRUG DEVELOPMENT SOLUTIONS
-
![Cytiva HyClone]( "Cell Culture Media For Viral Vector Production")
Support high-yield viral vector production with media designed for transfection efficiency, scalability, and reduced aggregation in HEK293 cells, ideal for AAV and LV workflows.
-
![biologics-GettyImages-2149749974]( "In Vitro Biology")
Curia’s discovery biology team accelerates your program toward the clinic and commercialization with our best-in-class, customizable solutions.
-
![HC-IS]( "Pharmaceutical Containment Isolators: HC-IS Series")
The primary characteristic of Containment Isolators is maximizing operator protection: Tema Sinergie Containment Isolator systems have been designed for handling high potent compounds and offer guaranteed very high levels of user protection.
-
![GettyImages-899692950-cleanroom-microscopes-scientists-analyze]( "High Potency Handling Capabilities And Support")
Highly potent APIs require stringent containment and precise manufacturing controls. Specialized facilities offer end-to-end development solutions and robust cross-contamination protections.
-
Decades of experience in production technologies, quality control and knowledge of the regulatory environment result in high-quality drug delivery devices that are fully optimized to perform as a system.
